T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy
Table 5
Prevalence values of the various T-cell subsets according to different anti-TNF therapies.
CD4
CD4/CD45RA
CD4/CD45RO
CD4/CD69
CD4/HLADR
CD8
CD8/CD45RA
CD8/CD45RO
CD8/HLADR
CD8/CD69
CD4/CD25
Th1
Th2
Th17
Treg
Infliximab
Median
37.20
5.11
43.80
2.57
4.57
14.35
6.09
5.25
4.94
0.72
0.76
8.97
7.17
2.47
5.810
25% percentile
26.55
1.83
22.00
0.85
3.18
8.89
1.98
4.21
3.66
1.00
0.97
18.40
8.22
1.83
4.590
75% percentile
47.20
8.74
50.20
5.22
6.76
19.53
19.83
12.18
6.96
1.90
3.21
19.55
10.53
4.24
7.128
Adalimumab
Median
29.45
3.24
51.15
1.50
6.02
14.10
4.78
11.29
5.20
0.46
0.50
16.65
7.34
3.01
5.665
25% percentile
16.71
2.07
30.04
0.85
3.86
5.675
1.60
5.010
1.67
0.88
1.01
21.00
8.24
2.26
4.273
75% percentile
37.03
10.42
62.28
2.37
10.02
23.55
6.44
15.75
9.78
1.75
2.07
23.40
9.72
4.17
7.318
Etanercept
Median
32.70
4.29
67.20
1.88
7.86
9.36
11.80
13.80
6.19
0.68
1.19
5.25
6.34
3.29
4.960
25% percentile
22.62
1.79
53.70
0.57
4.45
4.44
3.77
9.30
1.82
1.16
1.69
21.00
8.19
1.82
3.890
75% percentile
40.14
7.75
77.10
3.04
13.3
24.80
36.30
21.90
10.60
1.42
5.49
23.00
11.30
3.98
5.930
Certolizumab
Median
27.30
4.91
39.30
1.20
4.91
12.35
9.11
10.88
3.36
0.48
1.18
16.93
6.79
2.31
6.600
25% percentile
16.34
2.04
0.79
0.57
1.61
7.188
1.15
0.89
1.05
2.04
1.50
19.75
8.03
1.40
5.645
75% percentile
44.93
17.05
62.20
2.78
8.81
19.98
39.80
19.80
6.56
2.68
3.39
22.20
9.60
3.45
8.260
Golimumab
Median
24.09
2.64
35.50
0.83
5.72
6.76
6.29
14.30
7.14
0.23
0.58
16.80
6.00
2.66
6.765
25% percentile
18.75
0.62
5.710
0.16
4.65
2.12
1.72
3.79
3.91
0.68
1.12
23.55
6.68
1.67
6.008
75% percentile
44.08
11.61
55.45
2.29
9.32
12.42
16.95
16.15
14.79
1.71
1.44
30.53
9.28
3.15
6.923
Numbers indicate the median percentages and 25% and 75% percentile values within the whole T-cell population (CD4 and CD8 cells), or within CD4 cells (Th1, Th2, Th17, Treg, and ratios), or for the other markers within the CD4 or CD8 cells, as indicated.
